4-1BBz CD19-Her2tG (Seattle Children's Hospital)

N/A

Report date: 2022/03/24 10:32:03

Base Information

Drug Name4-1BBz CD19-Her2tG (Seattle Children's Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionAnti-CD19Receptor protein-tyrosine kinase erbB-2 antagonists
TargetsB-lymphocyte antigen CD19Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsLymphomaLeukemiaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSeattle Children'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesSeattle Children'S Hospital
Inactive CompaniesN/A
Active IndicationsLymphomaLeukemiaNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A